SCI时时刷

search
+
Effects of a six‐month low‐carbohydrate diet on glycemic control, body composition and cardiovascular risk factors in patients with type 2 diabetes: an open‐label RCT
Effects of a six‐month low‐carbohydrate diet on glycemic control, body composition and cardiovascular risk factors in patients with type 2 diabetes: an open‐label RCT
Abstract Aims To investigate the efficacy and safety of a non-calorie-restricted low-carbohydrate diet (LCD) on glycemic c...
Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post‐hoc analysis from the REWIND Randomized Trial
Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post‐hoc analysis from the REWIND Randomized Trial
Abstract Aims Diabetes mellitus is an independent risk factor for atrial fibrillation or atrial flutter (atrial arrythmia,...
Reduction of clinically important low glucose excursions with a long‐term implantable continuous glucose monitoring (CGM) system in adults with type 1 diabetes prone to hypoglycemia. France Adoption randomized clinical trial
Reduction of clinically important low glucose excursions with a long‐term implantable continuous glucose monitoring (CGM) system in adults with type 1 diabetes prone to hypoglycemia. France Adoption randomized clinical trial
Abstract Aim This trial assessed the outcomes on glucose control of the implantable Eversense real-time continuous glucose...
Acute effects of linagliptin on intact and total GLP‐1 and GIP levels in insulin‐dependent type 2 diabetic patients with and without moderate renal impairment
Acute effects of linagliptin on intact and total GLP‐1 and GIP levels in insulin‐dependent type 2 diabetic patients with and without moderate renal impairment
Abstract Aims Impaired renal function is a frequent complication in patients with type 2 diabetes mellitus (T2DM). The goa...
Understanding the clinical implications of differences between GMI and HbA1c
Understanding the clinical implications of differences between GMI and HbA1c
Abstract Laboratory measured glycosylated hemoglobin (HbA1c) is the gold standard for assessing glycemic control in people...
Quételet (Body Mass) Index and Effects of Dapagliflozin in CKD
Quételet (Body Mass) Index and Effects of Dapagliflozin in CKD
Abstract Aims This post-hoc analysis of DAPA-CKD (NCT03036150) assessed the effects of dapagliflozin in patients with chro...
Efficacy and safety of high‐dose GLP‐1, GLP‐1/GIP and GLP‐1/glucagon receptor agonists in type 2 diabetes
Efficacy and safety of high‐dose GLP‐1, GLP‐1/GIP and GLP‐1/glucagon receptor agonists in type 2 diabetes
Abstract Background GLP-1 receptor agonists (GLP-1 RAs) have become agents of choice for people with type 2 diabetes (T2D)...
Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period
Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period
Abstract Aims To evaluate the efficacy and safety of imeglimin for up to 52 weeks as combination therapy with insul...
Combined SGLT‐2 and ACE inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial
Combined SGLT‐2 and ACE inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial
ABSTRACT Aims Sodium glucose co-transporter-2 inhibitors (SGLT-2i) improve cardiorenal outcomes in chronic kidney disease ...
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
ABSTRACT Aims Bempedoic acid inhibits ATP-citrate lyase (ACL), an enzyme in the cholesterol synthesis pathway. Mendelian r...
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study
Abstract Aims The aim of RHINE-1, a double-blind, randomized, two-treatment, two-period, two-sequence crossover study, was...
Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow‐up (DPV) database
Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow‐up (DPV) database
Abstract Aim To assess the prevalence of elevated liver enzymes and associated diabetes-related comorbidities in type 2 di...
Improving beta‐cell secretory function and glycaemia in young‐onset type 2 diabetes: A pilot, 12‐month, randomized trial of a novel, continuous glucose monitor‐guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide
Improving beta‐cell secretory function and glycaemia in young‐onset type 2 diabetes: A pilot, 12‐month, randomized trial of a novel, continuous glucose monitor‐guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide
1 BACKGROUND Young-onset type 2 diabetes (YT2D) is characterized by poorer glycaemic control, a higher ...
Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial
Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial
Abstract Aim To evaluate the safety and efficacy of imeglimin for 52 weeks as monotherapy or combination therapy wi...
Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial
Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial
1 INTRODUCTION The prevalence of non-alcoholic fatty liver disease (NAFLD) is approximately 25% in both...
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes
Abstract Aims The glucagon-like peptide-1 analogue, semaglutide, has been co-formulated with the absorption enhancer, sodi...
Pushing the limits of insulin delivery 100 years later: A Case Study of a Race Across Canada
Pushing the limits of insulin delivery 100 years later: A Case Study of a Race Across Canada
This article has been accepted for publication and undergone full peer review but has not been through the co...
Real‐world data of 12‐month adjunct sodium‐glucose co‐transporter‐2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis
Real‐world data of 12‐month adjunct sodium‐glucose co‐transporter‐2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis
1 INTRODUCTION Sodium-glucose co-transporter-2 inhibitors (SGLT2is) represent a class of oral antidiabe...
Where can you wear your libre? Using the FreeStyle Libre Continuous Glucose Monitor on Alternative Sites
Where can you wear your libre? Using the FreeStyle Libre Continuous Glucose Monitor on Alternative Sites
Abstract Aims Subcutaneous continuous glucose monitoring (CGMS) has transformed management of Type 1 diabetes (T1DM). The ...
SGLT‐2 inhibitor for type 1 diabetes ‐ not any more?
SGLT‐2 inhibitor for type 1 diabetes ‐ not any more?
This article has been accepted for publication and undergone full peer review but has not been through the co...
The relationship between hypoglycaemia and glucose variability in type 1 diabetes
The relationship between hypoglycaemia and glucose variability in type 1 diabetes
1 INTRODUCTION Hypoglycaemia is a considerable barrier to intensified blood glucose management in type ...
Disparity in the rural‐urban distribution of clinical trial sites used in studies cited by diabetes treatment guidelines
Disparity in the rural‐urban distribution of clinical trial sites used in studies cited by diabetes treatment guidelines
1 INTRODUCTION The prevalence of diabetes and the associated complications are higher in rural areas in...
Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials
Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials
Abstract Aim To investigate the association between treatment with dulaglutide and glycaemic variability (GV) in adult pat...
Performance of intermittently scanned continuous glucose monitoring systems in people with type 1 diabetes: A pooled analysis
Performance of intermittently scanned continuous glucose monitoring systems in people with type 1 diabetes: A pooled analysis
Abstract Aims To conduct a pooled analysis to assess the performance of intermittently scanned continuous glucose monitori...
Metabolically healthy obesity and cardiovascular events: A risk of obesity
Metabolically healthy obesity and cardiovascular events: A risk of obesity
Corresponding Author Tomoyuki Kawada MD & PhD Departme...
Efficacy and Safety of Evogliptin in Patients with Type 2 Diabetes and Non‐Alcoholic Fatty Liver Disease: A Multicenter, Double‐blind, Randomized, Comparative trial
Efficacy and Safety of Evogliptin in Patients with Type 2 Diabetes and Non‐Alcoholic Fatty Liver Disease: A Multicenter, Double‐blind, Randomized, Comparative trial
Corresponding Author Byung-Wan Lee MD, PhD Division of End...
Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States
Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States
Abstract Aims To estimate the cost-effectiveness of sequential use of the sodium-glucose co-transporter 2 inhibitor empagl...
Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects
Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects
Corresponding Author Soo Lim MD Department of Internal Med...
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
Abstract Aims The sodium-glucose co-transporter-2 inhibitor empagliflozin reduced the total burden of cardiovascular morta...
Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population‐based analysis between 2010‐2020
Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population‐based analysis between 2010‐2020
Abstract Aim To examine trends in basal insulin prescribing in older adults with CKD. Materials and methods We conducted a...
阅读更多
format_indent_increase